Template:Transfusion risk: Difference between revisions
(/* Leukocyte Irradiated/Depleted RBCsTreleaven J et al. Guidelines on the use of irradiated blood components: Prepared by the BCSH Blood Transfusion Task Force. British Society for Haematology. Jan 2013. http://www.bcshguidelines.com/documents/irrad_bc...)
 
Line 38: Line 38:
| 1:4,700,000||Transmission of HIV per unit of component
| 1:4,700,000||Transmission of HIV per unit of component
|}
|}
===Leukocyte Irradiated/Depleted RBCs<ref>Treleaven J et al. Guidelines on the use of irradiated blood components: Prepared by the BCSH Blood Transfusion Task Force. British Society for Haematology. Jan 2013. http://www.bcshguidelines.com/documents/irrad_bcsh_072010.pdf</ref>===
*Gamma or X-radiated blood components to prevent [[Transfusion-associated graft-versus-host disease]] for at risk patients
*If tranfusion required for crashing patient, do not delay tranfusion of uncrossed blood to irradiate products
*Requires minimum 25 Gy irradiation, not to exceed 50 Gy for all:
**Packed red cells
**Platelets
**Granulocyte components, regardless of immunocompetency
**First or second degree relatives, regardless of immunocompetency
**HLA-selected components, regardless of immunocompetency
*Irradiated products should be administered shortly after irradiation
*Those products not used for intended recipient may be returned safely to stock for others not requiring irradiated components, though with reduced shelf life
*Not necessary to irradiate FFP, cryoprecipitate, fractioned plasma products
====At Risk Patients Requiring Irradiated Products====
*Congenital immunodeficiency syndromes (T-cell deficiencies)
*Neonates, especially if premature
*Exchange transfusions in pre-term and term infants
*Intrauterine transfusions
*Acquired immunodeficiencies to include:
**Lymphoma
**Leukemia
**Aplastic anemia
**Neutropenia
*Patients receiving:
*Stem cell transplants or harvesting
**Purine analogue chemotherapies (fludarabine, cladribine, deoxycoformicin, bendamustine, clofarabine, etc.)
**Certain biologic immunosuppresants (alemtuzumab)
====Not Routinely Needing Irradiated Products====
*HIV, AIDS
*Concurrent, non-severe common viral infection
*Rituximab treatment
*Routine solid organ transplant
*Routine infant cardiac surgery

Latest revision as of 01:43, 20 August 2016

Transfusion Risk Ratios[1]

Rate Complication
1:10 Febrile non-hemolytic transfusion reaction per pool of 5 donor units of platelets (1 pack)
1:100 Minor allergic reactions (urticaria)
1:300 Febrile non-hemolytic transfusion reaction per unit of RBC (1 pack)
1:700 Transfusion-associated circulatory overload per transfusion episode
1:5,000 Transfusion-related acute lung injury (TRALI)
1:7,000 Delayed hemolytic transfusion reaction
1:10,000 Symptomatic bacterial sepsis per pool of 5 donor units of platelets
1:40,000 Death from bacterial sepsis per pool of 5 donor units of platelets
1:40,000 ABO-incompatible transfusion per RBC transfusion episode
1:40,000 Serious allergic reaction per unit of component
1:82,000 Transmission of hepatitis B virus per unit of component
1:100,000 Symptomatic bacterial sepsis per unit of RBC
1:500,000 Death from bacterial sepsis per unit of RBC
1:1,000,000 Transmission of West Nile Virus
1:3,000,000 Transmission of HTLV per unit of component
1:3,100,000 Transmission of hepatitis C virus per unit of component
1:4,700,000 Transmission of HIV per unit of component
  1. ↑ Wagner, L. Why Should Clinicians Be Concerned about Blood Conservation? ITACCS. 2005 PDF
Retrieved from "https://www.wikem.org/w/index.php?title=Template:Transfusion_risk&oldid=95745"